Provides a multi-stakeholder perspective on the regulatory qualification and impact of novel digital endpoints like SV95C for Duchenne Muscular Dystrophy drug development.
Focusing on SV95C as a key example, we describe perspectives of multiple stakeholders on the promise of novel digital endpoints in neuromuscular disease drug development.
Servais et al. (Thu,) studied this question.